KAINOS Laboratories, Inc.

Tokyo Stock Exchange 4556.T

KAINOS Laboratories, Inc. Cash and Short-Term Investments for the year ending March 31, 2024: USD 20.97 M

KAINOS Laboratories, Inc. Cash and Short-Term Investments is USD 20.97 M for the year ending March 31, 2024, a -7.75% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • KAINOS Laboratories, Inc. Cash and Short-Term Investments for the year ending March 31, 2023 was USD 22.73 M, a 3.37% change year over year.
  • KAINOS Laboratories, Inc. Cash and Short-Term Investments for the year ending March 31, 2022 was USD 21.99 M, a 8.53% change year over year.
  • KAINOS Laboratories, Inc. Cash and Short-Term Investments for the year ending March 31, 2021 was USD 20.26 M, a 10.93% change year over year.
  • KAINOS Laboratories, Inc. Cash and Short-Term Investments for the year ending March 31, 2020 was USD 18.27 M.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
Tokyo Stock Exchange: 4556.T

KAINOS Laboratories, Inc.

CEO Mr. Yukihiro Nagatsu
IPO Date Jan. 4, 2000
Location Japan
Headquarters 38-18, Hongo 2-chome
Employees 133
Sector Health Care
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials
Description

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.

StockViz Staff

January 31, 2025

Any question? Send us an email